Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Paul Dockerty

Paul Dockerty

Customer Engagement Manager – Professional Services

Connect with Paul Dockerty on LinkedIn

About the author: Dr. Paul Dockerty has a Pharmacist degree from the University of Rouen, France, a M.S degree in Chemistry from the University Paris Descartes, France and a Ph.D in Chemical Biology from the University of Groningen, The Netherlands where he focused on the development of chemical probes based on a enol-carbamate scaffold. He works now as a Customer Engagement Manager in the Professional Services group at Elsevier and is responsible for supporting pharmaceutical customers in their digitalization journey.

Posts by Paul Dockerty

Readying Your Workforce for Digital Transformation

Posted on June 23rd, 2020 in Pharma R&D

Seeing it as key to innovation and competitive advantage, many businesses in the life sciences are learning to embrace digital transformation these days—in fact, with good reason, most view it as necessary for survival. But whether or not the process of adopting rapidly-evolving digital-age technologies will actually result in business success can really depend on how you do it.


A Systems Thinking Approach for Pharma

Posted on May 21st, 2020 in Chemistry

Systems thinking asks scientists to look at the bigger picture and take a more holistic approach to their work. Systems thinkers consider how their field of study might relate to other disciplines, and how their research might inform or benefit from the broader knowledge stream. 


Exploiting similarities between SARS-CoV-2 and other viruses to accelerate vaccine and therapy development

Posted on April 17th, 2020 in COVID-19

Coronavirus disease 19 (COVID-19) is now present in 230 countries, areas or territories around the world. As of April 15, 2020, the World Health Organization has reported 117,021 deaths [1]. Researchers across the globe are collaborating to develop antivirals and vaccines. In this context, understanding the vast amount of data published on SARS-CoV and other viruses is key to tackling the challenge of containing the 2019 novel coronavirus (SARS-CoV-2).